Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.
precision medicine – molecular profile – targeted treatment
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
05
2019
revised:
09
06
2019
accepted:
14
06
2019
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
20
8
2019
Statut:
epublish
Résumé
High-throughput genomic profiling of tumour specimens facilitates the identification of individual actionable mutations which could be used for individualised targeted therapy. This approach is becoming increasingly more common in the clinic; however, the interpretation of results from molecular profiling tests and efficient guiding of molecular therapies to patients with advanced cancer offer a significant challenge to the oncology community. MONDTI is a precision medicine platform for molecular characterisation of metastatic solid tumours to identify actionable genomic alterations. From 2013 to 2016, comprehensive molecular profiles derived from real-time biopsy specimens and archived tumour tissue samples of 295 patients were performed. Results and treatment suggestions were discussed within multidisciplinary tumour board meetings. The mutational profile was obtained from 293 (99%) patients and a complete immunohistochemical (IHC) and cytogenetic profile was obtained in 181 (61%) and 188 (64%) patients. The most frequent cancer types were colorectal cancer (12%), non-Hodgkin's lymphomas (9.8%) and head and neck cancers (7.8%). The most commonly detected mutations were The results reveal that the open concept for all solid tumours characterised for molecular profile and immunotherapy could not only match individualised treatment concepts at a high rate but also underscores the challenges encountered when offering molecularly matched therapies to a patient population with an advanced stage cancer.
Sections du résumé
BACKGROUND
BACKGROUND
High-throughput genomic profiling of tumour specimens facilitates the identification of individual actionable mutations which could be used for individualised targeted therapy. This approach is becoming increasingly more common in the clinic; however, the interpretation of results from molecular profiling tests and efficient guiding of molecular therapies to patients with advanced cancer offer a significant challenge to the oncology community.
EXPERIMENTAL DESIGN
METHODS
MONDTI is a precision medicine platform for molecular characterisation of metastatic solid tumours to identify actionable genomic alterations. From 2013 to 2016, comprehensive molecular profiles derived from real-time biopsy specimens and archived tumour tissue samples of 295 patients were performed. Results and treatment suggestions were discussed within multidisciplinary tumour board meetings.
RESULTS
RESULTS
The mutational profile was obtained from 293 (99%) patients and a complete immunohistochemical (IHC) and cytogenetic profile was obtained in 181 (61%) and 188 (64%) patients. The most frequent cancer types were colorectal cancer (12%), non-Hodgkin's lymphomas (9.8%) and head and neck cancers (7.8%). The most commonly detected mutations were
CONCLUSIONS
CONCLUSIONS
The results reveal that the open concept for all solid tumours characterised for molecular profile and immunotherapy could not only match individualised treatment concepts at a high rate but also underscores the challenges encountered when offering molecularly matched therapies to a patient population with an advanced stage cancer.
Identifiants
pubmed: 31423337
doi: 10.1136/esmoopen-2019-000538
pii: S2059-7029(20)30141-1
pmc: PMC6677998
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000538Déclaration de conflit d'intérêts
Competing interests: MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp and Dome. MK received travel support from Merck, Bayer, Bristol-Myers Squibb and Roche and has participated in advisory board meetings from Bayer and Servier.
Références
J Clin Oncol. 2003 Dec 1;21(23):4342-9
pubmed: 14645423
J Clin Oncol. 2010 Nov 20;28(33):4877-83
pubmed: 20921468
Cancer Discov. 2011 Jun;1(1):44-53
pubmed: 22586319
J Clin Oncol. 2012 Sep 10;30(26):3242-9
pubmed: 22649152
J Clin Oncol. 2013 Nov 10;31(32):4105-14
pubmed: 24101053
Lancet Oncol. 2014 Mar;15(3):267-74
pubmed: 24508104
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Clin Cancer Res. 2014 Sep 15;20(18):4827-36
pubmed: 24987059
Cancer Med. 2014 Oct;3(5):1136-45
pubmed: 25044252
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
J Clin Oncol. 2015 Sep 1;33(25):2753-62
pubmed: 26014291
N Engl J Med. 2015 Jun 4;372(23):2229-34
pubmed: 26014593
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Curr Treat Options Oncol. 2015 Nov;16(11):52
pubmed: 26374340
Oncotarget. 2015 Oct 20;6(32):33358-68
pubmed: 26396172
J Natl Cancer Inst. 2015 Nov 09;108(3):null
pubmed: 26553780
Cancer Treat Res. 2016;167:251-62
pubmed: 26601866
Am J Hematol. 2016 Jan;91(1):59-66
pubmed: 26769227
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
J Clin Oncol. 2016 Aug 20;34(24):2858-65
pubmed: 27022118
Nat Med. 2016 May 5;22(5):464-71
pubmed: 27149219
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Int J Biochem Cell Biol. 2016 Sep;78:173-179
pubmed: 27425397
Thyroid. 2016 Oct;26(10):1515-1516
pubmed: 27532222
N Engl J Med. 2016 Sep 29;375(13):1289-94
pubmed: 27682039
Genome Med. 2016 Oct 25;8(1):109
pubmed: 27782854
J Thorac Oncol. 2017 Apr;12(4):663-672
pubmed: 28007624
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
ESMO Open. 2016 Dec 15;1(6):e000084
pubmed: 28255450
Ann Oncol. 2017 May 1;28(5):1145-1151
pubmed: 28453708
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
JCO Precis Oncol. 2018;2018:
pubmed: 30027144
J Exp Med. 2018 Nov 5;215(11):2748-2759
pubmed: 30257862
Chin J Cancer Res. 2018 Oct;30(5):508-515
pubmed: 30510362
JCI Insight. 2019 Mar 7;4(5):null
pubmed: 30702443
J Thorac Oncol. 2019 May;14(5):876-889
pubmed: 30735816
Oncotarget. 2019 Jan 29;10(9):942-952
pubmed: 30847023